Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
02:01pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
10:30pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to imp
Factors Setting the Tone for HCA Healthcare (HCA) Q3 Earnings
05:40pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
HCA Healthcare's (HCA) third-quarter results are expected to reflect better emergency room visits and outpatient surgeries, partly offset by the continued incidence of labor costs.
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
02:43pm, Monday, 17'th Oct 2022 Zacks Investment Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
Expert Ratings for Biomarin Pharmaceutical
08:22pm, Thursday, 13'th Oct 2022 Benzinga
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
5
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
04:51pm, Thursday, 13'th Oct 2022 Zacks Investment Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
02:18pm, Thursday, 13'th Oct 2022
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.
Wall Street Analysts See a 31% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
01:55pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
The mean of analysts' price targets for BioMarin (BMRN) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
04:31pm, Friday, 07'th Oct 2022 Zacks Investment Research
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
01:33pm, Friday, 07'th Oct 2022
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
BioMarin Pharmaceutical: Leader In Rare Disease Innovation
11:11pm, Sunday, 02'nd Oct 2022
BioMarin Pharmaceutical's revenue was $533.8 million in Q2 2022, up 6.4% year-on-year. The company's net income has been growing at a substantial pace in recent quarters, helping to keep BioMarin Phar
BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy
05:24pm, Friday, 30'th Sep 2022 Zacks Investment Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to t
BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy
03:03pm, Friday, 30'th Sep 2022
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to t
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
09:37am, Thursday, 22'nd Sep 2022 The Motley Fool
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
05:37am, Thursday, 22'nd Sep 2022
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
